Skip to main content
2023 Guide to Patient Support Services

Coherus BioSciences

2023 PSS Guide

Coherus Solutions

844-483-3692

Coherus BioSciences’ Coherus Solutions offers comprehensive reimbursement and support services for patients receiving treatment with Udenyca (pegfilgrastim-cbqv) who are unable to afford this medication. The program also offers provider coding and billing services to facilitate appropriate billing and reimbursement.

Coherus Solutions

Coherus Solutions provides several financial assistance options for patients who have been prescribed Udenyca.

Co-Pay Assistance Program

This program covers out-of-pocket costs for eligible, commercially insured patients. Eligible patients may pay $0 for each dose of Udenyca, up to a maximum annual benefit of $15,000. Patients may be eligible if they:

  • Are prescribed Udenyca for a medically appropriate use
  • Have commercial health insurance that covers the medication costs of Udenyca
  • Do not participate in any federal, state, or government-funded healthcare program, such as Medicare, Medicaid, Medicare Advantage, Medicare Part D, Veterans Affairs, the Department of Defense, or TRICARE
  • Do not seek reimbursement amount received from Coherus from any third-party payers, including flexible spending accounts or healthcare savings accounts.

Patient Assistance Program

Udenyca may be provided to eligible uninsured and underinsured patients. Patients may be eligible if they:

  • Are uninsured or functionally underinsured
  • Are traditional Medicare FFS insured patient(s) who demonstrate financial hardship and cannot afford their cost-sharing obligation, as evidenced by a signed attestation from their provider
  • Have an adjusted annual household income of ≤500% of federal poverty level
  • Are under the care of a US licensed provider, and receive Udenyca in an established practice located in the US incident to the prescribing physician’s professional services in the outpatient setting
  • Are a United States resident of any US state
  • Are prescribed Udenyca for an FDA-approved indication
  • Do not have any other financial support options.

Provider Portal and Payer Coverage Tool

Provider support services are available through the Provider Portal as well as through the Payer Coverage Tool, which together facilitate access to reimbursement specialists and information about state-specific treatment coverage. Reimbursement support services include:

  • Assistance with the verification of insurance and benefits details
  • Udenyca-specific coding, billing details, and claims appeal process
  • Prior authorization requirements and facilitation.

Application and Enrollment

For information on enrollment in Coherus Solutions, call 844-483-3692 or visit the Coherus Solutions Provider Portal.

TABLE Coherus BioSciences Oncology Drug

Drug
Indication
Patient support programs

Drug
Udenyca (pegfilgrastim-cbqv)
Indication
Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia
Patient support programs

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)